Beyondspring Inc
BeyondSpring Inc (BYSI) is a small-cap, clinical-stage biotechnology company focused on oncology drug development. With a market capitalisation of about $88.71 million, the company’s near-term progress is driven largely by clinical trial readouts, regulatory interactions and potential collaborations or licensing deals. Investors should be aware that outcomes hinge on trial data and approvals, making the share price potentially volatile. As a development-stage business, BeyondSpring may require additional financing, which can dilute shareholders. This summary is for general educational purposes only and not personalised investment advice. The stock may suit investors with a higher risk tolerance who understand biotech-specific risks; values can rise or fall and past performance does not predict future results.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Beyondspring's stock with a target price of $1.25, indicating modest growth potential.
Financial Health
Beyondspring Inc is showing modest cash flow, indicating stability but with room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BYSI
FDA Cancer Warning: Beyond the Treatment Headlines
The FDA's new boxed warning for a major cancer therapy from Johnson & Johnson and Legend Biotech highlights the serious side effects of advanced treatments. This focus creates an investment opportunity in companies that develop drugs and therapies to help manage these adverse reactions, improving patient quality of life.
Published: October 12, 2025
Explore BasketChina's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
Trial readouts and regulatory progress are central to valuation; results can be binary and may cause significant share movement.
Potential catalysts
Upcoming study results, approvals or partnerships could change the outlook, though timings and outcomes are uncertain.
Small-cap dynamics
Lower market capitalisation can create higher volatility and liquidity constraints; suitable for investors who accept greater risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
